Development of Cyclic Tetrapeptide as an EGFR Tyrosine Kinase Inhibitor Assayed by ELISA Experiment and Docking Study: A Novel Approach

The first objective of this project is to synthesize innovative cyclic peptides and test them as Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) by Enzyme-Linked Immuno Sorbent Assay (ELISA) experiment. The Cyclic Phe-Phe-Phe-Gly Tetrapeptide (CPTP) exhibited a strong IC50 of 55.6 nM while cyclic heptapeptides, level. The second objective is to compare by AutoDock experiment the effectiveness between our most potent CPTP and US Food Drug Administration (FDA) approved erlotinib. The result of a docking study of the CPTP showed a fairy strong inhibition free energy of -7.74 kcal/mol. The two hydrogen bonds were observed between the donor hydrogen of CPTP and the acceptor oxygen of the EGFR residue PHE771, confirming the strong affinity between CPTP and EGFR protein. Cancer reveals the major mortality world-wide. The comprehensive understanding and strategy of cancer is inevitable for the diagnosis, treatment, and prevention of cancer. Various therapeutic techniques aimed at overcoming the resistance to currently available EGFR inhibitors and preventing its onset failed. Our honest goal is that our novel tetracyclic peptide will be a safe and effective treatment for non-small-cell lung cancer without causing resistance. We hope that the future clinical research will elucidate the fact that our novel CPTP is a resistant free and effective drug for the treatment of Non-Small-Cell (NCS) lung cancer.